Evidence map›Paper›PMID 33779077›Full record

ArticleEMBO molecular medicine2021

Therapy resistance on the RADar in ovarian cancer.

Jonas Schwickert, Franziska M Zickgraf, Martin R Sprick

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jonas SchwickertDivision of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-6332-7164
Franziska M ZickgrafDivision of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4269-1316
Martin R SprickDivision of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-9691-7574
German Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer has the worst prognosis of all gynecological cancers with high-grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high-grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).

Indexed as

Ovarian NeoplasmsRadarCarcinoma, Ovarian EpithelialFemaleHumans

Identifiers

PMID33779077
PMCPMC8103092
OpenAlexW3140174212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.